BCHE and early-onset autosomal dominant Alzheimer disease: Similarly, Donepezil and Rivastigmine are potent, selective, non-competitive, and rapidly reversible inhibitors of both acetylcholinesterase and butyrylcholinesterase, and are approved for the treatment of Alzheimer’s disease.